JB Pharma on Monday announced a 50% price cut for its heart failure drug Azmarda, which is a sacubitril-valsartan combination, in anticipation of stiff competition with the drug going off-patent in January 2023.
After the price reduction, Azmarda 50 mg will be available at Rs 39.6 per tablet as compared to Rs 78 per tablet. Azmarda is one of the top selling drugs of JB Pharma, with 17% market share.
“This is in line with our strategy of providing innovative and quality treatment to a larger patient pool at the most affordable price points,” he said.
“With this move, the overall monthly treatment cost will reduce significantly from ?4,500 to ?2,200. The heart failure drug also helps in reducing hospitalisation cost by about ?1,00,000 at the minimum,” he added.
“Heart failure is a devastating condition and it’s important to also increase awareness about the condition. Thus, JB will also institute over 300 ‘heart failure’ clinics across the country so that patients are able to detect the condition early and make informed health decisions,” he said further.
